{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:38:09Z","timestamp":1783355889702,"version":"3.54.6"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3196,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1002\/hep.21489","type":"journal-article","created":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T21:01:42Z","timestamp":1164747702000},"page":"1391-1393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?"],"prefix":"10.1097","volume":"44","author":[{"given":"Harry L. A.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241201","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0168-8278(02)00434-8","article-title":"BuddChiari syndrome: a review by an expert panel.","volume":"38","author":"Janssen","year":"2003","journal-title":"J Hepatol"},{"key":"R2-6-20241201","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMra020282","article-title":"The BuddChiari syndrome.","volume":"350","author":"Menon","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-6-20241201","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.510280505","article-title":"Proposal of a new nomenclature for BuddChiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion.","volume":"28","author":"Okuda","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R4-6-20241201","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/gut.49.5.720","article-title":"Extrahepatic portal vein thrombosis: aetiology and determinants of survival.","volume":"49","author":"Janssen","year":"2001","journal-title":"Gut"},{"key":"R5-6-20241201","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/gast.2001.21209","article-title":"Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.","volume":"120","author":"Condat","year":"2001","journal-title":"Gastroenterology"},{"key":"R6-6-20241201","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.510310307","article-title":"Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.","volume":"31","author":"Denninger","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R7-6-20241201","first-page":"2364","article-title":"Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with BuddChiari syndrome and portal vein thrombosis: results of a casecontrol study.","volume":"96","author":"Janssen","year":"2000","journal-title":"Blood"},{"key":"R8-6-20241201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-103-3-329","article-title":"Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with BuddChiari syndrome.","volume":"103","author":"Valla","year":"1985","journal-title":"Ann Intern Med"},{"key":"R9-6-20241201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with BuddChiari syndrome or portal vein thrombosis.","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"R10-6-20241201","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.","volume":"129","author":"Chait","year":"2005","journal-title":"Br J Haematol"},{"key":"R11-6-20241201","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1182\/blood.V91.6.2208","article-title":"Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood.","volume":"91","author":"Gomez","year":"1998","journal-title":"Blood"},{"key":"R12-6-20241201","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of lowdose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-6-20241201","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R14-6-20241201","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R15-6-20241201","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gainoffunction mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R16-6-20241201","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.","volume":"91","author":"ArellanoRodrigo","year":"2006","journal-title":"Haematologica"},{"key":"R17-6-20241201","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"R18-6-20241201","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the BuddChiari syndrome.","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"R19-6-20241201","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.","volume":"44","author":"Primignani","year":"2006","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21489","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200612000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:11:22Z","timestamp":1733058682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200612000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21489","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}